BJL
CRSP icon

Brighton Jones LLC’s CRISPR Therapeutics CRSP Stock Holding History

Brighton Jones LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,450
Closed -$216K – 633
2023
Q4 		$216K Buy
+3,450
New +$191K 0.01% 519
2023
Q3 		– Sell
-3,800
Closed -$213K – 551
2023
Q2 		$213K Buy
+3,800
New +$216K 0.01% 495
2022
Q4 		– Sell
-3,830
Closed -$250K – 483
2022
Q3 		$250K Sell
3,830
-61
-2% -$4.42K 0.01% 368
2022
Q2 		$236K Buy
3,891
+104
+3% +$6.11K 0.01% 385
2022
Q1 		$238K Buy
3,787
+85
+2% +$5.34K 0.01% 433
2021
Q4 		$281K Buy
3,702
+777
+27% +$67.9K 0.01% 389
2021
Q3 		$327K Buy
2,925
+451
+18% +$56.6K 0.02% 347
2021
Q2 		$401K Buy
2,474
+7
+0.3% +$851 0.02% 297
2021
Q1 		$301K Sell
2,467
-55
-2% -$8.3K 0.02% 311
2020
Q4 		$386K Buy
2,522
+16
+0.6% +$1.89K 0.02% 253
2020
Q3 		$210K Buy
+2,506
New +$222K 0.01% 307

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brighton Jones LLC's CRSP Position: Q1 2024 in Review

Brighton Jones LLC sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 3,450 shares — an estimated $216K sold.

Brighton Jones LLC first reported a position in CRSP in Q3 2020 and held it in 11 quarters. The position peaked at $401K in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • Brighton Jones LLC reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Brighton Jones LLC sold 3,450 CRISPR Therapeutics shares in Q1 2024, an estimated $216K.
  • Brighton Jones LLC first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 11 quarters.
  • Brighton Jones LLC's CRISPR Therapeutics position peaked at $401K in Q2 2021.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Brighton Jones LLC's 13F filing for Q1 2024, filed 9 May 2024.